As global diabetes prevalence continues to rise, insulin production must scale while meeting strict GMP and sterility requirements. This case study explores how industrial insulin manufacturing is designed, from biotechnology to aseptic formulation, and how Boccard supported a major producer in reinforcing formulation capacity.

Our teams have designed, manufactured, qualified and commissioned the key equipment for the largest blood fractionation plant in Canada of this Korean group.